HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance54% confidence

FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as ANI Pharmaceuticals.

Regulatory Analysis

Application ANDA209021. Sponsor: ASCENT PHARMS INC. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

Supporting Context

Therapeutic area
Pain Management · Opioid Combination
Sub-indication
Pain

Related signal: ANI Pharmaceuticals submits supplemental application for Oxycodone and Aspirin

Source

View source document

Related Signal

Open signal — ANI Pharmaceuticals submits supplemental application for Oxycodone and Aspirin
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.